Cases & Deals

Neurotech Pharmaceuticals raises $35 million in Series B round

Clients Neurotech Pharmaceuticals, Inc.

Jones Day represented Neurotech Pharmaceuticals, Inc., a biotechnology company focused on the development of sight-saving therapeutics for chronic eye diseases, in its issuance of $35 million of Series B Convertible Preferred Stock in a private placement to Burrill & Company, Versant Ventures, and SV Life Sciences.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.